<DOC>
	<DOC>NCT01751984</DOC>
	<brief_summary>This study will assess the LDL-C lowering efficacy and safety of ETC-1002 versus placebo in subjects with hypercholesterolemia and a history of statin intolerance.</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of ETC-1002 in Subjects With Statin Intolerance</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Key A history of statin intolerance that began during statin treatment and resolved within 4 weeks of stopping the statin treatment For subjects on current lipidregulating drugs LDLC 100220 mg/dL and triglycerides &lt;350 mg/dL (prior to washout of all lipidregulating drugs and supplements) For subjects not on current lipidregulating drugs LDLC 115270 mg/dL and fasting TG &lt;400 mg/dL Key Acute significant cardiovascular disease Poorly controlled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>lipid-lowering drugs</keyword>
	<keyword>statin intolerance</keyword>
</DOC>